Robert Weigle

Robert K. Weigle currently is and has been since April 1, 2023, the CEO of NOW Diagnostics. From October 2020 to March 2023, he was the CEO of AeenaDX, a saliva-based diagnostics company utilizing Genomics. Mr. Weigle is also currently an executive in residence with DigitalDX, a venture capital firm. Mr. Weigle was CEO and a director of Benvenue Medical from May 2009 until August 2020. Benvenue was a Silicon Valley based medical device company, which raised over $200 million in funding. At Benvenue Mr. Weigle led growth from pre-clinical to successful clinical trials to commercial launch of first-generation devices in two distinct markets, one for the treatment of compression fractures in the spine and the second for the treatment of degenerative disc disease, resulting in a first full year run rate exceeding $1 million per month. Mr. Weigle oversaw all early aspects of corporate strategy, including defining, communicating, and executing the company’s overall business model; and represented Benvenue to the investment community. Mr. Weigle was also a senior executive at numerous healthcare/medical device companies, including Johnson & Johnson, Baxter Healthcare, TherOx, Inc., (Zoll), Cardiac Pathways (Boston Scientific), and Camino Labs (Integra) Corp. Mr. Weigle was a member of the Board at Zyga (acquired by RTI) and currently is a Board member at Tenon, TNON NASDAQ. Mr. Weigle holds a BA from the University of California, Berkeley.